Results 171 to 180 of about 110,785 (312)

Age‐related differences in hydroxychloroquine‐associated adverse events: A pharmacovigilance study based on the FDA Adverse Event Reporting System

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Aims This real‐world pharmacovigilance study utilizes FDA Adverse Event Reporting System (FAERS) data (2004–2024) to characterize age‐related disparities in hydroxychloroquine (HCQ)‐associated adverse events (AEs), addressing gaps in age‐stratified risk assessment. Methods Disproportionality analysis (reporting odds ratios, RORs) and parametric Weibull
Guanghan Sun   +4 more
wiley   +1 more source

Pharmacokinetics and safety of tezepelumab in children with mild, moderate or severe asthma and adolescents with mild‐to‐moderate asthma

open access: yesBritish Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Tezepelumab is a human monoclonal antibody that blocks the activity of thymic stromal lymphopoietin and is approved for adolescents and adults with severe asthma. This analysis assessed pharmacokinetics (PK), pharmacodynamics and safety of tezepelumab up to 85 days postdose in adolescents and children.
Anna Lundahl   +14 more
wiley   +1 more source

Tissue adaptation of eosinophils. [PDF]

open access: yesJ Leukoc Biol
Lacroix CM, Kulkarni K, Diny NL.
europepmc   +1 more source

Reprogramming tumor immune microenvironment by ultrasound‐responsive nanoplatforms for enhanced cancer immunotherapy

open access: yesBMEMat, EarlyView.
Ultrasound‐responsive nanoplatforms reprogram the tumor immune microenvironment by targeting tumor cells, immune cells, and non‐immune stromal cells to enhance the efficacy of cancer immunotherapy. Abstract Cancer immunotherapy represents a significant advancement in cancer treatment by enhancing the specific recognition and elimination of cancer cells.
Shilong Zhao   +4 more
wiley   +1 more source

Baseline neutrophil-to-eosinophil-ratio and outcome in metastatic clear-cell renal cell carcinoma treated with nivolumab or ipilimumab/nivolumab [PDF]

open access: yes
Background and purpose: This study aims to evaluate neutrophil-to-eosinophil ratio (NER) as a prognostic and/or predictive biomarker in metastatic clear cell renal cell carcinoma (m-ccRCC) treated with nivolumab or ipilimumab/nivolumab.
Jessica Zucman-Rossi (4566949)   +15 more
core  

Histopathologic Analysis of the Morpho‐Functional Zones of the Human Acetabular Labrum

open access: yesClinical Anatomy, EarlyView.
ABSTRACT The structural and functional adaptation of soft tissues to mechanical load controls their ability to withstand injury and influences their capacity for healing. Similar to the knee meniscus, the acetabular labrum exhibits zonal differences in mechanical load distribution, resulting in distinct regions with unique structural and functional ...
Abdulaziz A. Alomiery   +4 more
wiley   +1 more source

Radiologic, Histologic and Scanning Electron Microscopic Characterization of the Peritoneal Reflection in Crohn's Disease

open access: yesClinical Anatomy, EarlyView.
ABSTRACT The peritoneal reflection bridges visceral and parietal peritoneum and lacks adjoining or underlying organs. As such it provides an opportunity to perform a focussed examination of the peritoneum in Crohn's disease. The aim of this study was to exploit this anatomical property and conduct a multilayered, focussed examination of the peritoneal ...
L. Walsh   +4 more
wiley   +1 more source

Serum and Nasal Lavage Fluid Eosinophil-Derived Neurotoxin Levels in Clinically Defined Asthma Phenotypes. [PDF]

open access: yesClin Transl Allergy
Özuygur Ermis SS   +15 more
europepmc   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

open access: yesClinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović   +11 more
wiley   +1 more source

Home - About - Disclaimer - Privacy